AFB-MTb antibiogram Moxifloxacin

The AFB-MTb antibiogram for Moxifloxacin is a laboratory test that assesses the susceptibility of Mycobacterium tuberculosis (MTB) to the fluoroquinolone antibiotic moxifloxacin. It is performed on AFB-positive respiratory specimens or cultured MTB isolates using standardized phenotypic drug susceptibility testing (including MIC determination) and, when available, genotypic assays that detect resistance-associated mutations (e.g., gyrA/gyrB).

This service is offered as a convenient home-sample collection in Dubai and the UAE, with specimens handled by DHA-accredited laboratories following biosafety protocols. Results—reported as MIC values and categorical interpretations (Sensitive / Intermediate / Resistant) and, where applicable, mutation findings—help TB specialists design effective regimens for drug-resistant TB, guide use of moxifloxacin in MDR-TB management, and avoid inappropriate empirical therapy.

Typical clinical indications include suspected or confirmed drug-resistant TB, treatment failure or relapse, prior fluoroquinolone exposure, and close contacts of MDR/XDR-TB cases. Turnaround times vary by method: rapid molecular-based resistance detection can be available within 1–3 days, while culture-based phenotypic susceptibility testing may require 2–6 weeks; clinical decisions should be made in consultation with a TB specialist and in line with Dubai Health Authority protocols.

• AFB smear microscopy
• Mycobacterium tuberculosis culture
• Phenotypic susceptibility to Moxifloxacin (MIC)
• Genotypic detection of gyrA/gyrB mutations
• Susceptibility interpretation (Sensitive / Intermediate / Resistant)

• Confirmed AFB-positive pulmonary TB requiring drug susceptibility data
• Poor clinical or microbiological response to first-line TB therapy
• Suspected or known MDR-TB, or contact of MDR/XDR-TB cases
• History of prior or prolonged fluoroquinolone use
• Relapse, recurrent TB, or immunocompromised patients (e.g., HIV)

• Determines suitability of Moxifloxacin in a patient’s TB regimen
• Home-sample collection for patient convenience and infection control
• Helps prevent ineffective therapy and further drug resistance
• Testing performed by DHA-accredited laboratories with standardized reporting
• Provides MIC and genotypic data to support specialist treatment decisions

• Early morning sputum (preferred) — collected at home by trained technician
• Inform provider of current TB treatment and any recent antibiotics
• No fasting required; avoid eating or smoking 1 hour before sputum collection
• Patient should follow infection-control instructions (wear mask until collection); samples transported under biosafety and DHA guidelines